S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
Log in
(Ad)
If you're looking to potentially make 1,000% in gains, then you NEED this biotech stock. This company discovered a medical breakthrough that may end heart attacks FOREVER! Estimated annual sales are $60 billion. The FDA has all but said it's going to approve the drug. Once that happens, the stock price could double overnight. But you must be onboard BEFORE FDA approval.

NASDAQ:PHAS - PhaseBio Pharmaceuticals Stock Price, Forecast & News

$5.63
-0.22 (-3.76 %)
(As of 01/21/2020 04:00 PM ET)
Today's Range
$5.50
Now: $5.63
$5.94
50-Day Range
$3.26
MA: $5.21
$7.45
52-Week Range
$2.56
Now: $5.63
$16.65
Volume349,172 shs
Average Volume917,119 shs
Market Capitalization$161.95 million
P/E RatioN/A
Dividend YieldN/A
Beta1.51
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. It is also developing PB1046, a fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is based in Malvern, Pennsylvania.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PHAS
CUSIPN/A
CIKN/A
Phone610-981-6500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$670,000.00
Book Value$2.08 per share

Profitability

Net Income$-23,850,000.00
Net Margins-1,768.29%

Miscellaneous

Employees22
Market Cap$161.95 million
Next Earnings Date3/24/2020 (Estimated)
OptionableNot Optionable

Receive PHAS News and Ratings via Email

Sign-up to receive the latest news and ratings for PHAS and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

Located just 25 miles from Cleveland... is a supergreenhouse unlike anything we've ever seen. Listed at over 1.4 million sq ft, (the size of 9 full-sized Costco warehouses), this marijuana grow house is capable of producing over 341,000 pounds of weed/year! And very soon it will come online and could turn a tiny 60-cent pot company into the dominator in the white-hot weed market.

PhaseBio Pharmaceuticals (NASDAQ:PHAS) Frequently Asked Questions

What is PhaseBio Pharmaceuticals' stock symbol?

PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS."

How were PhaseBio Pharmaceuticals' earnings last quarter?

PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) issued its earnings results on Thursday, November, 14th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by $0.04. The business earned $0.24 million during the quarter, compared to analysts' expectations of $0.35 million. PhaseBio Pharmaceuticals had a negative return on equity of 53.00% and a negative net margin of 1,768.29%. View PhaseBio Pharmaceuticals' Earnings History.

When is PhaseBio Pharmaceuticals' next earnings date?

PhaseBio Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for PhaseBio Pharmaceuticals.

What price target have analysts set for PHAS?

5 analysts have issued 12 month price targets for PhaseBio Pharmaceuticals' shares. Their forecasts range from $17.00 to $27.00. On average, they anticipate PhaseBio Pharmaceuticals' share price to reach $20.67 in the next twelve months. This suggests a possible upside of 267.1% from the stock's current price. View Analyst Price Targets for PhaseBio Pharmaceuticals.

What is the consensus analysts' recommendation for PhaseBio Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PhaseBio Pharmaceuticals.

Has PhaseBio Pharmaceuticals been receiving favorable news coverage?

Media headlines about PHAS stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. PhaseBio Pharmaceuticals earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for PhaseBio Pharmaceuticals.

Are investors shorting PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 2,290,000 shares, an increase of 16.8% from the December 15th total of 1,960,000 shares. Based on an average daily trading volume, of 474,800 shares, the days-to-cover ratio is presently 4.8 days. Approximately 16.5% of the company's shares are sold short. View PhaseBio Pharmaceuticals' Current Options Chain.

Who are some of PhaseBio Pharmaceuticals' key competitors?

What other stocks do shareholders of PhaseBio Pharmaceuticals own?

Who are PhaseBio Pharmaceuticals' key executives?

PhaseBio Pharmaceuticals' management team includes the folowing people:
  • Mr. Jonathan P. Mow, Pres, CEO & Director (Age 54)
  • Mr. John P. Sharp, Chief Financial Officer (Age 54)
  • Dr. John S. Lee, Chief Medical Officer (Age 51)
  • Mr. Clay Bernardin Thorp, Chairman (Age 51)
  • Mr. Michael B. York, VP of Corp. Devel. & Commercial Strategy (Age 54)

When did PhaseBio Pharmaceuticals IPO?

(PHAS) raised $66 million in an initial public offering (IPO) on Thursday, October 18th 2018. The company issued 5,000,000 shares at a price of $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.

Who are PhaseBio Pharmaceuticals' major shareholders?

PhaseBio Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include FNY Investment Advisers LLC (0.03%). Company insiders that own PhaseBio Pharmaceuticals stock include Clay Thorp, John P Sharp, Jonathan P Mow, Linda Tufts, Michael York, Nancy J Hutson and Venture Advisors Iii Hatteras. View Institutional Ownership Trends for PhaseBio Pharmaceuticals.

Which institutional investors are buying PhaseBio Pharmaceuticals stock?

PHAS stock was purchased by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. Company insiders that have bought PhaseBio Pharmaceuticals stock in the last two years include Clay Thorp, John P Sharp, Jonathan P Mow, Linda Tufts, Michael York, Nancy J Hutson and Venture Advisors Iii Hatteras. View Insider Buying and Selling for PhaseBio Pharmaceuticals.

How do I buy shares of PhaseBio Pharmaceuticals?

Shares of PHAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is PhaseBio Pharmaceuticals' stock price today?

One share of PHAS stock can currently be purchased for approximately $5.63.

How big of a company is PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals has a market capitalization of $161.95 million and generates $670,000.00 in revenue each year. The company earns $-23,850,000.00 in net income (profit) each year or ($4.49) on an earnings per share basis. PhaseBio Pharmaceuticals employs 22 workers across the globe.View Additional Information About PhaseBio Pharmaceuticals.

What is PhaseBio Pharmaceuticals' official website?

The official website for PhaseBio Pharmaceuticals is http://www.phasebio.com/.

How can I contact PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The company can be reached via phone at 610-981-6500 or via email at [email protected]


MarketBeat Community Rating for PhaseBio Pharmaceuticals (NASDAQ PHAS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  89 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  192
MarketBeat's community ratings are surveys of what our community members think about PhaseBio Pharmaceuticals and other stocks. Vote "Outperform" if you believe PHAS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PHAS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2020 by MarketBeat.com Staff

Featured Article: Hedge Funds Explained

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel